In the Isotope Products segment, sales increased by 7% to EUR 95.8 million. The increase in sales was spread across all product areas.
Due to the deconsolidation of the tumor irradiation business, sales in the Medical segment declined by 2% to EUR 84.5 million. Adjusted for this one-time effect, the segment generated additional sales growth compared to the previous year. The growth driver continues to be the pharmaceutical radioisotope business.

Cash and cash equivalents as of December 31, 2021 amounted to EUR 93.7 million. Compared to the end of 2020, this corresponds to an increase of EUR 6.2 million. As the company continues to operate profitably and self-financing, the Executive Board considers itself well equipped with cash for upcoming growth investments.

For the current fiscal year 2022, the Executive Board expects an increase in sales to around EUR 200 million and a net income of around EUR 38 million. The forecast is based on a weighted average exchange rate of USD 1.20 per EUR and is subject to the assumption that no major disruptions continue to result from the developments in Ukraine.

The Executive Board and Supervisory Board will propose a dividend of EUR 0.50 per dividend-bearing share (previous year: EUR 0.45) to the Annual Shareholders‘ Meeting.

The full 2021 financial statements can be found here:
https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/deutsch/euzj21e.pdf